Educational Program in Skin Self-Examination To Detect Melanoma in Healthy Participants

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Rhode Island Hospital
ClinicalTrials.gov Identifier:
NCT00416988
First received: December 27, 2006
Last updated: June 19, 2013
Last verified: July 2008
  Purpose

RATIONALE: An educational program may be effective in increasing monthly skin self-examinations to detect melanoma in healthy participants.

PURPOSE: This randomized clinical trial is studying how well an educational program works in increasing monthly skin self-examinations to detect melanoma in healthy participants.


Condition Intervention
Melanoma (Skin)
Weight Changes
Other: educational intervention

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Prevention
Official Title: Skin Self-Examination for Early Detection of Melanoma: Intervention and Consequence

Resource links provided by NLM:


Further study details as provided by Rhode Island Hospital:

Estimated Enrollment: 1135
Detailed Description:

OBJECTIVES:

  • Determine the incidence of monthly thorough skin self-examinations (TSE) for early detection of melanoma in healthy participants who are under routine care by their primary care physician.
  • Determine the impact of the intervention package and the resulting change in TSE performance, in terms of visits to healthcare providers for skin problems, in these participants.
  • Evaluate the efficacy of this intervention package in improving performance of TSE in these participants.
  • Estimate potential effect of this intervention on health care resource use.

OUTLINE: This is a controlled, randomized study.

Two weeks prior to their appointment with their physician, participants undergo a baseline assessment. During the appointment, participants are randomized to 1 of 2 intervention arms.

  • Arm I (control): Participants receive written educational materials and watch a video on healthy dietary habits during their appointment. They receive nutrition tip sheets, including information related to reducing fat, saturated fat, and cholesterol in the diet, at 2 and 6 months after their initial appointment. Participants also undergo telephone assessments at 2, 6, and 12 months after their initial appointment.
  • Arm II (skin self-examinations): Participants undergo a 10- to 15-minute face-to-face counseling session with the study intervention specialist and receive training in thorough skin self-examination (TSE) directly after their appointment. They also receive written educational materials and watch a 25-minute video designed to motivate and teach them to do TSE. Two weeks later, participants receive a follow-up call from the same study intervention specialist. Participants receive tailored feedback at 2 and 6 months and a motivational postcard at 4 months after their initial appointment. Participants also undergo telephone assessments as in arm I.

Participating physicians seeing participants in both arms attend a 60-minute educational session regarding skin cancer detection, prevention, identification, and triage, supplemented by written materials. They are also trained and prompted to deliver a 30-second message emphasizing the desirability of performing monthly TSE during their appointment with participants.

After completion of the study intervention, participants are offered the educational materials of the intervention arm to which they were not randomized.

PROJECTED ACCRUAL: A total of 1,135 participants will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

DISEASE CHARACTERISTICS:

  • Healthy participants who are scheduled for a routine or health maintenance visit with a participating primary care office that meets all of the following criteria:

    • At least 50% of patients are being seen for regular ongoing general medical care
    • Specializes in internal medicine (subspecialties allowed), family medicine, or obstetrics/gynecology
    • Employs at least 2 physicians who meet all of the following requirements:

      • Agree to participate
      • Work full-time, defined as at least 8 sessions per week of 3 or more hours
      • Completed post-graduate training
      • Not a federal employee or full-time hospital-based faculty
      • Have been in practice at least 1 year
      • Not planning on relocating or retiring within the next 3 years

PATIENT CHARACTERISTICS:

  • Must be able to read in either English or Spanish
  • Has no household member who has been previously enrolled on this study, including a person who has the same telephone number or address
  • Not in acute discomfort
  • Able to comply with intervention
  • No impairment that would preclude skin self-examination
  • Must be able to view video
  • No illness or disability that would preclude participation in the study interview

PRIOR CONCURRENT THERAPY:

  • Must not have been previously enrolled on this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00416988

Sponsors and Collaborators
Rhode Island Hospital
Investigators
Study Chair: Martin A. Weinstock, MD, PhD Rhode Island Hospital
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00416988     History of Changes
Other Study ID Numbers: CDR0000454855, RIH-R01-CA78800
Study First Received: December 27, 2006
Last Updated: June 19, 2013
Health Authority: United States: Federal Government

Keywords provided by Rhode Island Hospital:
melanoma
weight changes

Additional relevant MeSH terms:
Body Weight Changes
Melanoma
Body Weight
Signs and Symptoms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas

ClinicalTrials.gov processed this record on July 23, 2014